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In Brief
Clarke et al. show that levels of the
initiator tRNAi
Met are increased in
carcinoma-associated fibroblasts. Using
a transgenic approach to recapitulate this
in vivo and quantitative mass
spectrometry to characterize the stromal
secretome, they show that elevated
tRNAi
Met drives production of a type II
collagen-rich ECM to drive tumor
progression.
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Expression of the initiator methionine tRNA (tRNAi
Met)
is deregulated in cancer. Despite this fact, it is not
currently known how tRNAi
Met expression levels influ-
ence tumor progression.We have found that tRNAi
Met
expression is increased in carcinoma-associated
fibroblasts, implicating deregulated expression of
tRNAi
Met in the tumor stromaas a possible contributor
to tumor progression. To investigate how elevated
stromal tRNAi
Met contributes to tumor progression,
we generated a mouse expressing additional copies
of the tRNAi
Met gene (2+tRNAi
Met mouse). Growth
and vascularization of subcutaneous tumor allografts
was enhanced in 2+tRNAi
Met mice compared with
wild-type littermate controls. Extracellular matrix
(ECM) deposited by fibroblasts from 2+tRNAi
Met
mice supported enhanced endothelial cell and fibro-
blast migration. SILAC mass spectrometry indicated
that elevated expression of tRNAi
Met significantly
increased synthesis and secretion of certain types of
collagen, in particular type II collagen. Suppression
of type II collagen opposed the ability of tRNAi
Met-
overexpressing fibroblasts to deposit pro-migratory
ECM. We used the prolyl hydroxylase inhibitor ethyl-
3,4-dihydroxybenzoate (DHB) to determine whether
collagen synthesis contributes to the tRNAi
Met-driven
pro-tumorigenic stroma in vivo. DHB had no effect
on the growth of syngeneic allografts in wild-type
mice but opposed the ability of 2+tRNAi
Met mice to
support increased angiogenesis and tumor growth.
Finally, collagen II expression predicts poor prog-
nosis in high-grade serous ovarian carcinoma. TakenCurtogether, these data indicate that increased tRNAi
Met
levels contribute to tumor progression by enhancing
the ability of stromal fibroblasts to synthesize and
secrete a type II collagen-rich ECM that supports
endothelial cell migration and angiogenesis.
INTRODUCTION
The use of transcriptomics and proteomics to understand
cellular function has been pivotal in advancing our knowledge
of the molecular basis of disease processes, and the combined
use of these approaches is beginning to highlight discord be-
tween the control of gene expression at the levels of transcription
and translation. Indeed, implementation of numerous post-tran-
scriptional processes means that expression of particular genes
at the mRNA level does not necessarily correlate with cellular
concentrations of functional products of the same transcripts.
tRNAs are one of the most-abundant RNAs in eukaryotic cells,
yet are frequently disregarded in most genome-wide analyses
because they are assumed to be background genes with merely
housekeeping functions. However, it is now becoming clear that
cellular levels of tRNAs are key to the control of gene expression
in a number of different contexts. Indeed, tissue-specific differ-
ences in tRNA expression occur across a variety of human tis-
sues, with relative levels of tRNAs correlating to the codon usage
of highly expressed genes in those tissues [1]. Indeed, the avail-
ability of certain tRNAs may be controlled in the cell in order to
regulate the efficiency of translation of certain gene transcripts.
This may, in turn, allow the cell to regulate the activity of certain
pathways [2]. For instance, proliferating cells have increased
levels of tRNAs that are specific for codons overrepresented in
pathways required for proliferation. A number of publications
have demonstrated that tRNA levels may be increased in cancer
[3–5], and although it was previously unknown whether this was
a cause or consequence of carcinogenesis, recent work fromrent Biology 26, 755–765, March 21, 2016 ª2016 The Authors 755
Gingold et al. [2] highlighted the possibility that tRNA expression
could indeed play a role in carcinogenesis itself.
There has also been some focus on the consequences of
altered expression of specific tRNAs, including tRNAi
Met, the
initiator methionine tRNA responsible for recognizing the start
codon and initiating translation. Whereas one group indicated
that overexpression of tRNAi
Met may reprogram global tRNA
expression levels and increase proliferation of human epithelial
cells [6], another showed that increased levels of tRNAi
Met influ-
ences the growth ofDrosophila larvae largely owing to increased
secretion of insulin-related peptides from fat bodies [7]. This
in vivo observation that tRNAi
Met levels can drive protein secre-
tion is particularly interesting. It indicates that tRNAi
Met-sensitive
translational control may contribute to cancer progression not
only by altering gene expression of the cancer cells themselves
but also by altering the secretome of other cells that support
carcinogenesis [8–10].
In the current study, we find that levels of tRNAi
Met are
increased in cancer-associated fibroblasts (CAFs) by compari-
son to normal fibroblasts. To further understand the conse-
quences of altered stromal expression of tRNAi
Met, we generated
a transgenic mouse that carries two additional copies of the
tRNAi
Met gene (2+tRNAi
Met mouse). We found that this leads to
enhanced tumor growth and enhanced tumor vascularization.
In terms of mechanism, we show that increased tumor growth
in 2+tRNAi
Met mice is due to elevated secretion of type II collagen
by fibroblasts which, in turn, supports migration of endothelial
cells, leading to increased tumor vascularity. Our data therefore
provide the first evidence that tRNAi
Met levels selectively drive
secretion of specific components of the extracellular matrix
(ECM) to support tumor progression.
RESULTS
Increased Expression of tRNAi
Met in the Host Animal
Promotes Tumor Growth and Angiogenesis
To determine whether tRNA expression is altered in the tumor
stroma, we measured tRNA levels in immortalized human mam-
mary carcinoma-associated fibroblasts (iCAFs) and compared
these with immortalized matched normal fibroblast (iNF) con-
trols. iCAFs were generated by co-injecting iNFs with Ras-trans-
formed MCF7 cells subcutaneously into mice [11]. These iCAFs
are established to have an enhanced capacity to promote tumor
growth and angiogenesis when co-injected as xenografts with a
variety of tumor cell types and are established to maintain their
myofibroblast-like phenotype when grown in culture [11]. We
characterized these cells for the expression of non-coding
RNA transcribed by RNA polymerase III. Importantly, increased
expression of tRNAi
Met and the tRNA for isoleucine (tRNAIle)
was seen in iCAFs by comparison with iNFs, whereas no change
was detected in the expression of the 5S rRNA, another non-
coding RNA transcribed by RNA polymerase III (Figure S1).
To investigate the consequences of increased stromal
tRNAi
Met, we generated a transgenic mouse that carries two
extra copies of the tRNAi
Met gene inserted into the genome at
the HPRT locus (2+tRNAi
Met mouse; Figure S2A). 2+tRNAi
Met
animals have elevated levels (1.3- to 1.5-fold) of tRNAi
Met in a
number of tissues, including fibroblasts from lung and from
whole-mouse embryos (MEFs) (Figure S2B). 2+tRNAi
Met animals756 Current Biology 26, 755–765, March 21, 2016 ª2016 The Authorwere the same size and weight as their littermate controls (not
shown), and MEFs isolated from 2+tRNAi
Met embryos did not
have altered rates of cellular protein synthesis (measured by
35S-methionine incorporation) or cell proliferation (Figures S2C
and S2D). We introduced syngeneic tumor cells into 2+tRNAi
Met
mice as subcutaneous allografts and recorded their growth.
Initially, we used transformed melanoblasts derived from Tyr::
NrasQ61K/;INK4a/ mice. These transformed melanoblasts
are null for INK4a, express mutant NRas under a melanoblast-
specific promoter, and form melanomas in syngeneic host
mice [12]. Mice were culled once tumors reached a specified
size (15 3 15 mm), which we defined as the clinical endpoint in
order to perform Kaplan-Meier survival analysis. Importantly, tu-
mors reached clinical endpoint significantly faster in 2+tRNAi
Met
mice than they did in wild-type littermate controls (Figure 1A).
To confirm this observation of enhanced tumor growth in
2+tRNAi
Met mice, we also measured the growth of Lewis lung
carcinoma (LLC) and B16 F0 melanoma allografts. Both allo-
graft models formed significantly larger and more-vascularized
tumors in 2+tRNAi
Met mice than they did when grown in wild-
type littermate control animals (Figures 1B and 1C), indicating
that increased tRNAi
Met expression in the host animal can pro-
mote increased tumor growth and tumor angiogenesis.
Increased Stromal tRNAi
Met Expression Promotes the
Deposition of a Pro-migratory ECM via Release of
Secreted Factors
A key component of the tumor microenvironment that dictates
cancer cell behavior is the ECM deposited by stromal fibro-
blasts. To determine whether tRNAi
Met levels influence the char-
acteristics of fibroblast-derived ECM, we isolated fibroblasts
from the lungs and embryos of 2+tRNAi
Met mice (Figure S2B)
and used these to prepare cell-derived matrices using estab-
lished methods [13, 14]. We then investigated the capacity of
this cell-free ECM to support the migration of other cells.
ECM deposited by primary cultured fibroblasts from 2+tRNAi
Met
mice had significantly enhanced ability to support migration of
both endothelial cells (Figure 2A) and fibroblasts (Figure 2B)
by comparison with ECM deposited by cells from their wild-
type littermate controls. As a tool to determine how increased
tRNAi
Met expression influences ECM deposition, we generated
independent pools of immortalizedmouse embryonic fibroblasts
(iMEF) transfected with either tRNAi
Met (iMEF-tRNAi
Met) or an
empty vector control (iMEF-vector) (Figure S3A). Consistent
with our observations in primary cultured MEFs, increased
tRNAi
Met expression did not lead to increased cell proliferation
or cellular protein synthesis in immortalized MEFs (Figures S3B
and S3C). However, ECM deposited by iMEF-tRNAi
Met cells
had a similarly enhanced ability to support increased cell migra-
tion as did the ECM secreted by primary cultured fibroblasts
from 2+tRNAi
Met mice (Figure 3A).
To determine whether the relationship between tRNAi
Met
expression and the deposition of pro-migratory ECM was
observable in fibroblasts from human tumors, we obtained
primary CAFs from two human breast tumors and compared
these with fibroblasts isolated from the surrounding normal tis-
sue (>5 cm from the tumor) from the same patients. The CAFs
from patient 1 displayed significant upregulation of tRNAi
Met by
comparison with fibroblasts from surrounding normal tissue,s
Figure 1. Increased Expression of tRNAi
Met in the Host Animal Pro-
motes Angiogenesis and Growth of Allografts
(A) 1 3 106 transformed melanocytes (Tyr::NrasQ61K/;INK4a/) were in-
jected subcutaneously into either wild-type (WT) or 2+tRNAi
Met transgenic
male mice and tumor size monitored. Mice were culled once tumors reached
endpoint (15 3 15 mm in size). Kaplan-Meier survival curves were plotted
based on time taken to reach endpoint. n = 14 (WT); n = 14 (2+tRNAi
Met mice);
log rank (Mantel-Cox) test; *p < 0.05.
(B) 1 3 106 LLC cells were injected subcutaneously into either wild-type (WT)
or 2+tRNAi
Met transgenic male mice, and tumors were harvested at 21 days.
The graph on the right shows final tumor volume ± SEM. Tumors were
fixed and stained to visualize endomucin for blood vessel identification and
vessels counted across the entire tumor section. Graph on the left shows
tumor vessel density ± SEM; n = 10 (WT); n = 10 (2+tRNAi
Met); unpaired t test;
*p < 0.05.
(C) 0.5 3 106 B16 F0 mouse melanoma cells were injected subcutaneously
into either wild-type (WT) or 2+tRNAi
Met transgenic mice. The time at which
palpable tumors were formed was recorded (minimum size of 3 3 3 mm) and
then tumors were harvested 22 days from this time point. Tumors were
fixed and stained to visualize endomucin for blood vessel identification and
vessels counted across the entire tumor section. The graph on the right
shows final tumor volume ± SEM. The graph on the left shows tumor vessel
density ± SEM; n = 20 (WT); n = 20 (2+tRNAi
Met); unpaired t test; *p < 0.05;
**p < 0.005.
Curbut this was not observed in the second patient (patient 2) (Fig-
ure S4A). Interestingly, the ECM produced by CAFs from patient
1 supported significantly increased cell migration, whereas the
CAF-derived ECM from patient 2 did not (Figure S4B). These
data indicate that, although upregulation of tRNAi
Met in CAFs
varies between patients, the relationship between tRNAi
Met
levels and the ability to generate pro-migratory ECM may be
observed in primary cultured CAFs from human tumors.
Many ECM components are initially secreted by fibroblasts
as soluble proteins that are subsequently incorporated into the
insoluble ECM. To determine which of these stages of ECM
deposition are influenced by tRNAi
Met levels, we collected condi-
tioned medium from iMEF-tRNAi
Met and iMEF-vector cells and
incubated these with normal iMEFs, which were, in turn, allowed
to deposit ECM. Interestingly, ECM deposited by iMEFs cultured
in conditioned medium from tRNAi
Met-overexpressing cells had
significantly enhancedability tosupport cellmigration (Figure3B),
indicating that tRNAi
Met levels control the synthesis and secretion
of soluble ECM components rather than the ability of fibroblasts
to remodel these and incorporate them into insoluble ECM.
Cell migration may be influenced by themechanical properties
of the ECM. ECM stiffness promotes cell migration, and certain
secreted enzymes (such as lysyl oxidases and transglutami-
nases) catalyze the formation of covalent cross-links between
amino acid chains to increase ECM stiffness. We used atomic
force microscopy (AFM) to measure the mechanical properties
of ECM and found that cell-derived matrix generated in the pres-
ence of conditionedmedium from tRNAi
Met-overexpressing cells
did not consistently differ in its thickness or stiffness from that
generated in the presence of conditioned medium from control
cells (Figure 3C). Taken together, these data indicate that
increased tRNAi
Met expression supports deposition of a pro-
migratory ECM via release of secreted components that do not
influence the mechanical properties of the ECM.
Increased tRNAi
Met Levels Drive a Secretome that Is
Enriched in Type II Collagen
We used SILAC-based mass spectrometry to quantitatively
determine the influence of tRNAi
Met levels on the complement
of soluble proteins secreted by fibroblasts. We labeled iMEF-
tRNAi
Met and iMEF-vector cells with light and heavy SILAC amino
acids, respectively (forward [Fw] labeling), and with heavy and
light amino acids, respectively (reverse [Rev] labeling). We then
prepared cell extracts, and for the secretome, we used an affinity
bead (Strataclean)-based approach to enrich for proteins
secreted into serum-free conditioned medium [15]. Proteomes
were detected using an LTQ-Orbitrap, and mass spectrometry
data were analyzed with the MaxQuant computational platform,
which identified proteins in the proteome and in the secretome
(Tables S1 and S2) with high correlation between Fw and Rev
experiments. Analysis of the cellular proteome indicated that
increased tRNAi
Met levels disproportionately increased the
synthesis of proteins destined for secretion (Figure 4A; Table
S1) whereas not greatly affecting the production of cellular
non-secreted components. By contrast, the composition of the
secretome was significantly altered by increased expression of
tRNAi
Met (Figures 4B and 4C). Indeed, tRNAi
Met overexpres-
sion lead to enhanced production of many secreted ECM com-
ponents, including collagens and collagen-processing enzymesrent Biology 26, 755–765, March 21, 2016 ª2016 The Authors 757
Figure 2. Fibroblasts Isolatedfrom2+tRNAi
Met
TransgenicMiceDeposit aPro-migratoryECM
(A) Extracellular matrix (ECM) was generated from
primary lung fibroblasts isolated from either wild-
type (WT) or 2+tRNAi
Met transgenic mice. See Fig-
ure S2 for characterization of these cells. Migration
of human umbilical vein endothelial cells (HUVECs)
on the ECM was recorded by time-lapse micro-
scopy and analyzed using ImageJ. Data represent
ECM generated from seven independent isolates
of primary fibroblasts from pools of three WT and
three 2+tRNAi
Met transgenic mice, tracking the
migration of at least 28 HUVECs in each replicate.
Box and whisker plot represents 5–95 percentile;
Mann-Whitney test; ****p < 0.0001.
(B) ECM was generated from primary fibroblasts
isolated from either WT or 2+tRNAi
Met primary
mouse embryonic fibroblasts (MEFs)—these cells
are characterized in Figure S2. Migration of
immortalized MEFs (iMEFs) on the ECM was re-
corded by time-lapse microscopy over a 17-hr time
course and analyzed using ImageJ. Data represent
ECM generated from primary fibroblasts from two
pairs of litter-matched WT and 2+tRNAi
Met trans-
genic mice, tracking the migration of at least
60 iMEFs in each replicate; n = 3 for pair 1; n = 2
for pair 2. Box and whisker plot represents 5–95
percentile; Mann-Whitney test; ****p < 0.0001.(Figure 4C). In particular, type II collagen secretion by fibroblasts
was upregulated by at least 50-fold following tRNAi
Met overex-
pression in these cells (Figures 4B and 4C; Table S2). Further-
more, specificity in the nature of the secreted ECM components
was observed in iMEF-tRNAi
Met cells, which did not necessarily
correlate with protein abundance (Figure 4D). For example,
despite the observation that fibronectin was one of the most-
abundant proteins in the secretome, its levels were not signifi-
cantly altered following tRNAi
Met overexpression (Figures 4C
and 4D). Upregulated expression of a given protein is commonly
associated with increased recruitment of its mRNA(s) to actively
translating ribosomes (polysomes). We used sucrose density
gradients to determine whether increased tRNAi
Met levels were
able to drive polysomal recruitment of collagen II mRNA. We
found no indication that the monosome/polysome ratio differed
between iMEF-vector and iMEF-tRNAi
Met cells (Figure S5A),
which is consistent with our observations that the overall
levels of cellular protein synthesis were unaffected by increased
tRNAi
Met levels (Figures S2C and S3C). However, iMEF.tRNAi
Met
cells displayed markedly increased polysomal content of
collagen II mRNA (Figure S5B). Conversely, polysomal associa-
tion of mRNAs for fibronectin and the ARPP0 ribosomal protein
with polysomes was unaffected by increased tRNAi
Met levels
(Figures S5C and S5D).
Immunostaining of ECM deposited by two independent
tRNAi
Met-overexpressing cell lines confirmed that upregulation
of soluble secreted type II collagen was also reflected by its758 Current Biology 26, 755–765, March 21, 2016 ª2016 The Authorsincreased incorporation into the insoluble
ECM (Figure 4E). We examined whether
levels of tRNAi
Met in the stroma influences
the collagen II content of tumors in vivo.
To do this, we introduced LLC cells intowild-type and 2+tRNAi
Met mice as syngeneic allografts, allowed
the tumors to grow for 21 days, and then stained them for
collagen II. Collagen II deposition was clearly visible in the
spaces between tumor cells, and quantitative analysis indicated
that the collagen II content of tumors grown in 2+tRNAi
Met
animals was significantly higher than it was in tumors from litter-
mate control animals (Figures 5A and 5B).
Type II Collagen Secretion Is Required for tRNAi
Met to
Drive Production of Pro-tumorigenic ECM
To assess whether type II collagen secretion is responsible
for the ability of tRNAi
Met to deposit a pro-migratory ECM, we
generated cell-derived matrices from iMEFs cultured with condi-
tioned media from iMEF-tRNAi
Met cells transfected with type II
collagen-specific siRNA or non-targeting control. Knockdown
of type II collagen in iMEF-tRNAi
Met cells resulted in conditioned
mediumwith decreased ability to enable iMEFs to generate ECM
that supported fibroblast migration (Figures 6A and S6A–S6C).
Furthermore, knockdown of type II collagen (with two indepen-
dent siRNA sequences) in primary lung fibroblasts isolated
from 2+tRNAi
Met mice similarly compromised the ability of the
ECM derived from these cells to support increased migration
of endothelial cells (Figure 6B).
ECM was also made from iMEFs in which type II collagen
levels had been suppressed using CRISPR genome editing
(MEF-tRNAi
Met/collagen II CRISPR; Figures S6D and S6E). Im-
munostaining indicated significantly decreased type II collagen
Figure 3. tRNAi
Met Supports Deposition of
Pro-migratory ECM via Release of Secreted
Factors
(A) Migration of iMEFs on ECM was recorded
by time-lapse microscopy over a 17-hr period
and analyzed using ImageJ. ECM was gener-
ated using immortalized fibroblasts (iMEFs) stably
overexpressing either empty vector (iMEF-vector)
or tRNAi
Met (iMEF-tRNAi
Met). See Figure S3 for
characterization of these cells.
(B) ECM was generated by iMEFs in the presence
of conditioned media from iMEF-vector or iMEF-
tRNAi
Met cells. All data represent ECM generated
from at least three independent ECM isolations,
tracking the migration of at least 40 iMEFs in each
replicate. Box and whisker plot represents 5–95
percentile; Mann-Whitney test; ****p < 0.0001.
(C) Atomic force microscopy and contact imaging
wereperformedusinga JPKNanoWizard II BioAFM
incombinationwithaBrukerMLCTcantilever and to
measure the thickness of ECM following wound
scratch or a Nanoworld Arrow TL-1 cantilever with
bead attached for force spectroscopy; n = 3 inde-
pendent ECM generations; ±SEM; ****p < 0.0001;
ns, no significant difference; Kruskal-Wallis test.incorporation into ECM deposited by MEF-tRNAi
Met/collagen II
CRISPR cells (Figure 6C, left panel). Consistently, ECM gener-
ated by MEF-tRNAi
Met/collagen II CRISPR fibroblasts had
decreased ability to support increased cell migration (Figures
6C, right panel, and S6F).
We then determined whether collagen synthesis was required
for generation of a pro-tumorigenic microenvironment in vivo.
To do this, we used ethyl-3,4-dihydroxybenzoate (DHB), a prolyl
hydroxylase inhibitor that is well-established to compromise
collagen processing in vivo and thus prevents collagen secre-
tion in vivo [16]. Indeed, DHBadministration significantly reduced
the collagen II content of allografted tumors in both wild-type
and tRNAi
Met mice (Figures 5A and 5B). However, whereas
DHB treatment did not affect vascularity or growth of LLC subcu-Current Biology 26, 755–76taneous allografts in WT mice, it signifi-
cantly opposed the increased vascularity
and growth of tumors seen in 2+tRNAi
Met
mice (Figure 5C), indicating that collagen
production is indeed required for tRNAi
Met
to drive tumor growth and angiogenesis
in vivo.
Type II Collagen Expression
Predicts Poor Prognosis in Ovarian
Cancer
To determine whether the relationship
between increased collagen II levels and
tumor progression is observable in human
cancer, we stained a tissue microarray
containing 62 cases of primary ovarian
tumors. The decision to focus on this can-
cer type was influenced by reports that
ovarian cancer aggressiveness is particu-
larly associated with increased angio-genesis [17]. In univariate analysis, high collagen II histoscores
were associated with significantly decreased survival following
resection of primary ovarian tumors (Figure 7), and this was
particularly apparent in high-grade serous carcinoma (Figure S7).
Indeed, patients with tumors displaying a collagen II histoscore
greater than 50 have a2.992-fold increasedhazard ratio for death
(p = 0.0002). These data indicate that collagen II expression is a
significant factor in driving the progression of ovarian cancer.
DISCUSSION
Regulation of the cellular tRNA repertoire is thought to dictate
selectivity of translational programs to influence cancer progres-
sion and to define cell fates [2]. Indeed, the tRNA repertoire5, March 21, 2016 ª2016 The Authors 759
Figure 4. tRNAi
Met Drives a Secretome that
Is Enriched in Type II Collagen
(A) The cellular proteome was analyzed following
tRNAi
Met overexpression using quantitative SILAC
mass spectrometry. iMEF-vector and iMEF-
tRNAi
Met cells were labeled with heavy and light
amino acids. Cells were lysed and proteins sepa-
rated by gel electrophoresis and analyzed by
mass spectrometry. Forward experiment (Fw)
corresponds to iMEF-tRNAi
Met labeled with heavy
amino acids combined with iMEF-vector light
amino acids, and the reverse experiment (Rev)
corresponds to iMEF-vector heavy-labeled amino
acids combined with iMEF-tRNAi
Met light amino
acids. ECM proteins are highlighted in red.
(B) The secretome was analyzed following
tRNAi
Met overexpression using quantitative SILAC
mass spectrometry. Cells were labeled as for (A),
and conditioned medium was collected. Proteins
were concentrated from conditioned medium us-
ing Strataclean beads and subjected to mass
spectrometry analysis as for (A). ECM proteins are
highlighted in red.
(C) A table of the most significantly upregulated
secreted proteins identified in conditionedmedium
following tRNAi
Met overexpression. Upregulated
ECM proteins are highlighted in red.
(D) Data from (B) replotted to show the total
abundance of secreted proteins identified in the
media of iMEF-tRNAi
Met against the fold change
in expression of the same proteins in the iMEF-
tRNAi
Met compared to iMEF-vector. ECM proteins
are highlighted in red.
(E) ECM was generated from iMEF-vector and
iMEF-tRNAi
Met cells. Incorporation of collagen II
into the ECM was assessed by immunostaining
using type II collagen-specific antibodies and
quantified using the Aerius infrared imaging sys-
tem (LI-COR Biosciences).differs between proliferating and differentiated cells, and this is
thought to influence the translational landscape according to
codon usage [2, 18]. Thus, an mRNA with a preponderance
of a given codon will be translated more rapidly if the tRNA
recognizing that codon is abundant. Consequently, one might
anticipate that increased tRNAi
Met (which recognizes AUG at
translation start sites) would generally increase translation initia-
tion and globally upregulate protein synthesis and cell growth [6].
However, our transgenic approach has given no indications that
increased tRNAi
Met levels promote cell growth or proliferation
in a cell-autonomous fashion, nor does this greatly influence
the quantity or profile of cellular protein synthesis. Instead, we
have found that increased levels of tRNAi
Met lead to highly selec-
tive adjustments to the protein synthesis landscape that are
restricted to certain secreted proteins—particularly the ECM
component, type II collagen. There is evidence from studies
in Drosophila that elevated tRNAi
Met controls production of
secreted proteins. Introduction of one extra copy of the tRNAi
Met
gene into flies is sufficient to markedly enhance larval growth [7].760 Current Biology 26, 755–765, March 21, 2016 ª2016 The AuthorsConsistent with our findings, this is pri-
marily not attributable to a cell-autono-
mous drive to cell growth and prolifera-tion in the developing organs. Rather, growth is driven by an
endocrine relay in which increased tRNAi
Met in fat body cells
promotes secretion of factor(s) that trigger release of insulin-
like peptides from brain neurosecretory cells that, in turn, circu-
late throughout the larvae to promote growth of developing
organs and tissues [7].
ECM production constitutes a significant commitment to the
cell (both in terms of load on the ER and the biosynthetic machin-
ery), indicating the need for special mechanisms to be in place
to control the translation of ECM proteins and other abundant
components of the fibroblast secretome. Expression of type I
collagens is known to be controlled at the level of mRNA stability
and translation, due to unique 50 stem loops in their 50 UTRs [19],
and the production of these fibrillar collagens by the stroma is
established to influence cancer growth and metastasis [20, 21].
Type II collagen is also a fibrillar collagen; however, little is known
about how its production might be controlled post-transcription-
ally. Although the sensitivity of collagen II production to tRNAi
Met
levels indicates that translation initiation is likely a key point of
Figure 5. Collagen II Production Is Required for tRNAi
Met to Drive Production of a Pro-tumorigenic ECM
1 3 106 LLC cells were injected subcutaneously into either WT or 2+tRNAi
Met transgenic male mice, followed by daily administration of ethyl-3,4-dihydrox-
ybenzoate (DHB) (40 mg/kg) or vehicle control. Tumors were harvested 21 days following injection. Tumor volumes were measured and tumor sections were
stained for collagen II or endomucin.
(A and B) Collagen II staining in LLC tumors harvested from WT and 2+tRNAi
Met mice treated with vehicle or DHB as indicated (A). Collagen II staining was
quantified by using the Image J ‘‘threshold color’’ plug-in to highlight the brown staining in the left panels and to render this as a grayscale image as shown in
(legend continued on next page)
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Figure 6. Collagen II Secretion Is Required
for tRNAi
Met to Drive Production of a Pro-
migratory ECM
(A) ECM was generated from iMEFs in the pres-
ence of conditioned media from iMEF-tRNAi
Met
cells treated with non-targeting (siNT) or type-II-
collagen-specific siRNA (siCollagen II). Migration
of immortalized MEFs (iMEFs) on the ECM was
recorded by time-lapse microscopy over a 17-hr
time course and analyzed using ImageJ. See Fig-
ures S6A–S6C for a schematic representation of
the protocol for this experiment, the validation of
the siRNA, and representative examples of the
migration track plots.
(B) ECM was generated from primary lung fibro-
blasts treated with non-targeting (siNT) or type-II-
collagen-specific siRNA (siCollagen II). Two inde-
pendent pools of fibroblasts from 2+tRNAi
Met mice
were used as indicated. Migration of human um-
bilical vein endothelial cells (HUVECs) on the ECM
was recorded by time-lapse microscopy and
analyzed using ImageJ.
(C) ECM was generated from iMEF-vector, iMEF-
tRNAi
Met, and iMEF-tRNAi
Met with type II collagen II
stable knockdown (iMEF-tRNAi
Met Collagen II
CRISPR). Incorporation of collagen II into the ECM
was assessed by immunostaining using type-II-
collagen-specific antibodies, quantified using the Aerius infrared imaging system (LI-COR Biosciences); unpaired t test; *p < 0.05; **p < 0.005. Migration of iMEFs
was recorded as previously described. Data represent ECM generated from at least three independent ECM isolations, tracking themigration of at least 40 iMEFs
in each replicate. Box and whisker plot represents 5–95 percentile; Kruskal-Wallis test; ****p < 0.0001; ns, not significant. See Figures S6D–S6F for a schematic
representation of the protocol for this experiment, the validation of the CRISPR, and representative examples of the migration track plots.control of type II collagen synthesis, there are indications that
the mechanism for this might not be straightforward. Indeed,
in some cells (including those used for the polysome analysis
displayed in Figure S5), we find that tRNAi
Met overexpression
increases the cellular levels of mRNA for type II collagen (not
shown), indicating that tRNAi
Met levels may influence transcrip-
tion or stability of mRNAs for ECM proteins. Thus, despite clear
indications that tRNAi
Met levels selectively control ECM protein
synthesis in a way that influences tumor outcomes, further
work will be needed to fully establish the molecular mechanisms
through which tRNAi
Met levels influence type II collagen synthe-
sis and the contribution made by the translational machinery to
this non-cell-autonomous drive to tumor progression.
Despite the presence of a number of tRNAi
Met-sensitive com-
ponents in the fibroblast secretome, it is clear that suppression
of just one of these, type II collagen, is sufficient to negate the
tRNAi
Met phenotype. Moreover, we have shown that stromal
levels of type II collagen are strongly associated with aggressive-
ness of serous ovarian carcinoma, indicating the importance of
this tRNAi
Met-sensitive secreted factor to the progression of a
human cancer type. However, we have been unable to quantita-
tively determine tRNAi
Met levels in human tumor microarrays,
and it will be necessary to do this to conclusively determine
whether stromal tRNAi
Met drives type II collagen synthesis in
human tumors in the same way as we have demonstrated bythe right-hand panels. Bar, 50 mm. Graph in (B) shows quantification of collagen
vehicle or DHB.
(C) Graphs show tumor volumes (right-hand graph) and quantification of endomu
fromWT and 2+tRNAi
Met mice treated with vehicle or DHB as indicated. Values ar
n = 7 (2+tRNAi
Met; DHB); unpaired t test; *p < 0.05; **p < 0.001; ns, no significan
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Met mouse model. Type II
collagen is an abundant component of cartilage and is produced
in large quantities by chondrocytes. By contrast, normal fibro-
blasts are not thought to secrete collagen II, and consistently,
our SILAC data show that this collagen is a relatively minor
component of the fibroblast secretome. Thus, acquisition of
type II collagen secretion when tRNAi
Met levels are increased
may represent a shift to a more-chondrocyte-like phenotype,
and this may be consistent with the role for the tRNA repertoire
in influencing differentiation state [2]. In view of this, one might
anticipate that increased tRNAi
Met levels may be associated
with production of ECM with cartilaginous features, such as
increased stiffness. However, our AFM data show clearly
that ECM produced by fibroblasts with increased tRNAi
Met
levels does not have consistently altered compliance, indi-
cating that type II collagen content is not necessarily linked
to stiffness. In addition to providing mechanical support, a
key role of the ECM is to act as a reservoir for growth factors
and other bioactive proteins. The tRNAi
Met secretome contains
a number of pro-tumorigenic growth factors (such as frizzled-
related protein and TGF-b2), and we are currently considering
the possibility that type II collagen production is associated
with secretion of these growth factors and their incorporation
into the ECM, increasing their presentation to tumor and endo-
thelial cells.II staining in LLC tumors harvested from WT and 2+tRNAi
Met mice treated with
cin-positive tumor blood vessel density (left-hand graph) in harvested tumors
e mean ± SEM; n = 8 (WT; vehicle); n = 7 (2+tRNAi
Met; vehicle); n = 8 (WT; DHB);
t difference.
s
Figure 7. Type II Collagen Expression
Predicts Poor Prognosis in Ovarian Cancer
A tissue microarray (TMA) containing 62 cases of
ovarian cancer was stained for type II collagen.
Examples of tumor cores displaying low (left side)
and high (right side) histoscores for collagen II are
displayed in (A). (B) shows a Kaplan-Meier anal-
ysis of patient survival when the cohort is divided
into tumors with low (histoscore < 50) and high
(histoscore > 50) collagen II expression. Patients
with tumors displaying a collagen II histoscore
greater than 50 have a 2.992-fold increased hazard
ratio for death; p = 0.0002 (log rank test); n = 62.
See Figure S7 for Kaplan-Meier analysis of the
relationship between collagen II levels in the high-
grade serous subset of these tumors.Targeting the translational initiation machinery with drugs has
been shown to have sufficiently selective effects on protein syn-
thesis in tumor cells to influence cancer progression. Indeed,
eIF4A, which is the molecular target for the promising anticancer
agent silvestrol, favors translation of key oncoproteins such as
Myc, Notch, and BCL2 [22]. Our findings indicate that control
of tRNAi
Met levels in stromal fibroblasts is key to the generation
of a collagen-II-rich pro-tumorigenic microenvironment, and
this will provide further impetus to the search for drugs to manip-
ulate translation initiation and ECM synthesis in cancer.
Our data also have implications for understanding the mecha-
nisms of tumor angiogenesis. Although stromal fibroblasts are
known to contribute to angiogenesis in tumors, the mechanisms
through which fibroblasts promote tumor angiogenesis are
incompletely understood [23]. The data presented here suggest
that the secretion of a pro-migratory ECM by stromal fibroblasts
is an important mechanism via which stromal fibroblasts pro-
mote angiogenesis in cancer.
EXPERIMENTAL PROCEDURES
Cell Culture
Primary MEFs were isolated from embryonic day 13 (E13)–E15 WT or
2+tRNAi
Met embryos. After sterile dissection from the yolk sac and removal
of the fetal liver and head, the embryo was disaggregated by forceful pipetting
and cells pelleted by centrifugation and resuspended in DMEM supplementedCurrent Biology 26, 755–76with 10% FBS, 200 mM L-glutamine, 100 U/ml
penicillin streptomycin, 0.25 mg/ml Fungizone,
and 50 mM b-mercaptoethanol. Cells were cultured
on 0.1% gelatin-coated plates and used as
described in the text. For routine culture, human
umbilical vein endothelial cells (HUVECs) from
pooled donors (TCS Cell Works) were seeded
onto 0.1% gelatin-coated plates and cultured in
M199 medium supplemented with 20% FBS,
0.1 mg/ml bovine brain endothelial mitogen,
1 ng/ml heparin, and 100 U/ml penicillin strepto-
mycin. HUVECs were used for experiments at
passages 4–8. Both B16F0 and LLC cells were
cultured in DMEM supplemented with 10% FBS.
Animal Experimentation
All animal work was carried out with ethical
approval (University of Glasgow and Institute of
Cancer Research) in dedicated barrier animal facil-
ities proactive in environmental enrichment and inaccordance with the revised Animals (Scientific Procedures) Act 1986 and
the EU Directive 2010/63/EU.
2+tRNAi
Met Mice
Two copies of the murine tRNAi
Met gene (tRNA78), including 140 bp of
flanking sequence, were targeted into the HPRT locus of HM1 embryonic
stem cells and used to generate chimeric mice. 2+tRNAi
Met transgenic
offspring were derived by crosses to C57Bl/6 mice and maintained on a
C57Bl6/J background.
Syngeneic Allografts
Cells were injected subcutaneously into the right flank of either WT or
2+tRNAi
Met transgenic mice. Tumors were harvested at 21 or 22 days post-
implantation (for LLC and B16) or at endpoint (for melanocytes), and final tumor
volume was calculated using the formula (L3W3W)/2, where L is the longest
dimension andW is the shortest dimension. For blood vessel identification, tu-
mors were fixed and stained for endomucin. Vessels were counted across the
entire tumor section and are reported as vessels/mm2. Only tumors of a similar
size were counted, with extremely large and extremely small tumors excluded
to allow for reasonable biological comparison. Selection of tumors to analyze
was made before blood vessel counts. Forty milligrams per kilogram DHB was
administered daily by intraperitoneal injection.
Expression Vectors
Fragments containing tRNAi
Met were initially cloned into the multiple
cloning site of the pLPCX vector using EcoRI. The pLPCX-tRNAi
Met construct
and pLHCX final destination vector were digested using BglII and ClaI and
ligated to produce the pLHCX-tRNAi
Met-containing vector. The vector was
digested with HpaI and SnaBI and then re-ligated. For CRISPR gene editing,5, March 21, 2016 ª2016 The Authors 763
single-stranded oligonucleotides were designed to exon 1 of collagen II,
annealed to make double-stranded oligos, and ligated into the linearized
GeneArt CRISPR Nuclease Vector as per manufacturer’s instructions (Life
Technologies).
qRT-PCR
RNA was prepared using Trizol (Life Technologies) and cDNA prepared using
Quantitech Reverse Transcription Kit (QIAGEN), both as per manufacturer’s
instructions, using 5, 10, and 20 ng RNA templates to ensure the reaction
was quantitative. qPCR was conducted using SyBr green (Quanta) and the
Bio-RadCFX platform, with a 60C annealing temperature and the primer pairs
that are tabulated in the Supplemental Experimental Procedures.
siRNA Transfection
iMEFs were transfected with 10 nM collagen II siRNA (L-043139-01-0005
mouse Col2a1 SMARTpool; Dharmacon), or non-targeting siRNA, using the
Amaxa Nucleofector system, solution R, program T-20, as per manufacturer’s
instructions (Lonza). Cellswere used for experiments at 48hr post-transfection.
ECM Generation and Cell Migration
The preparation of cell-derived matrix was performed as previously described
[14], as was time-lapse analysis of cell migration [13].
AFM
To measure the thickness of ECMs following wound scratch, AFM force spec-
troscopy and contact imaging were performed using a JPK NanoWizard II Bio
AFM in combination with a Bruker MLCT cantilever. A Nanoworld Arrow TL-1
cantilever with bead attached was used for force spectroscopy.
SILAC Mass Spectrometry
iMEF-vector and iMEF-tRNAi
Met cells were labeled with light (Arg0/Lys0;
Sigma) and heavy amino acids (Arg10/Lys8; Cambridge Isotopes Labora-
tories). In the case of the forward experiment, iMEF-vector cells were labeled
with light amino acids and iMEF-tRNAi
Met cells with heavy amino acids,
whereas in the reverse experiment, iMEF-vector cells were labeled with heavy
amino acids and iMEF-tRNAi
Met cells with light amino acids. Briefly, cells were
passaged in SILAC DMEM containing light or heavy amino acids supple-
mented with 10% FBS for three passages and then transferred to media con-
taining light or heavy amino acids supplemented with 10% dialyzed FBS. Cells
were cultured for 48 hr at 37C/5% CO2, washed twice with PBS, and trans-
ferred into serum-free media for 6 hr at 37C/5% CO2. The media was then
acidified to pH 5 with 10% TFA and 10 ml Strataclean beads added per 1 ml
media. Beads were collected by brief centrifugation and proteins separated
by electrophoresis. Proteins were digested with 0.05 mg/ml trypsin in 50 mM
ammonium bicarbonate overnight. Extracted digests were stage tipped and
analyzed on a linear trap quadrupole (LTQ)-Orbitrap Elite. Data were searched
and quantified against Uniprot MOUSE using MaxQuant [24].
Tissue Microarray and Immunohistochemistry
The SaPPrOC trial (Clinicaltrials.gov reference NCT01196741) was a random-
ized phase II study of weekly paclitaxel ± oral saracatinib in women with
relapsed, platinum-resistant ovarian cancer. The study was approved by the
UK National Research Ethics Service (reference 10/H1211/26), and the pri-
mary outcome data are reported elsewhere [25]. A tissue microarray was
created with triplicate 5-mm cores from formalin-fixed paraffin-embedded
tumor material collected at the time of diagnosis. Five-micrometer sections
from formalin-fixed paraffin-embedded tumors were stained for collagen II
expression (Dako Autostainer). Stained slides were digitized (Hamamatsu
NanoZoomer NDP; Hamamatsu Photonics) and viewed using Slidepath Digital
Image Hub V4.0.7 (Leica Microsystems). Areas of tumor were identified and
scored using Slidepath Tissue Image Analysis and histoscores generated by
multiplying intensity of cellular staining within marked areas (range 0–3) by per-
centage tumor cells with positive staining (range 0–100), with a maximum his-
toscore of 300. Data represent mean histoscore per tumor.
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